Detalles de la búsqueda
1.
Phase I/II clinical trial of efficacy and safety of EGCG oxygen nebulization inhalation in the treatment of COVID-19 pneumonia patients with cancer.
BMC Cancer
; 24(1): 486, 2024 Apr 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38632501
2.
Immunotherapy as a later-line option for HER2-altered advanced non-small-cell lung cancer: taxane might be a favorable partner.
Future Oncol
; 19(33): 2251-2261, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37909261
3.
Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2).
BMC Med
; 20(1): 277, 2022 08 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-36031613
4.
Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas harboring KRAS and BRCA mutations: case report and whole exome sequencing analysis.
BMC Gastroenterol
; 20(1): 202, 2020 Jun 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-32590950
5.
Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment.
Chin J Cancer Res
; 31(2): 349-356, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31156305
6.
Concomitant double-fusion of PLEKHA7-ALK and INPP5D-ALK reveals favorable alectinib sensitivity in lung adenocarcinoma: a case report and literature review.
Discov Oncol
; 15(1): 43, 2024 Feb 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38379102
7.
Dacomitinib exhibits promising activity against the rare HER2 exon 20 insertion M774delinsWLV in lung cancer: A case report and literature review.
Heliyon
; 10(9): e30312, 2024 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38707278
8.
The efficacy and safety of chemo-free therapy in epidermal growth factor receptor tyrosine kinase inhibitor-resistant advanced non-small cell lung cancer: A single-arm, phase II study.
Cancer Med
; 12(19): 19438-19448, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37723846
9.
First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China.
Cancer Med
; 12(1): 335-344, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35608132
10.
Pyrotinib plus antiangiogenic agents for HER2-altered advanced non-small cell lung cancer: A retrospective real-world study.
Thorac Cancer
; 14(33): 3275-3281, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37740599
11.
Organ-specific immune checkpoint inhibitor treatment in lung cancer: a systematic review and meta-analysis.
BMJ Open
; 13(3): e059457, 2023 03 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36931679
12.
EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors.
Front Pharmacol
; 13: 984503, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36425568
13.
EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors.
Front Pharmacol
; 13: 976731, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36188595
14.
Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China.
Front Pharmacol
; 13: 919652, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35770100
15.
The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors.
Front Oncol
; 12: 843299, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35223527
16.
First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2-altered NSCLC: a retrospective real-world POLISH study.
Ther Adv Med Oncol
; 14: 17588359221082339, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35251321
17.
Specific HER2 Exon 20 Gly776 Deletion-Insertions in Non-Small Cell Lung Cancer: Structural Analysis and Sensitivity to HER2-Targeted Tyrosine Kinase Inhibitors.
Front Pharmacol
; 13: 806737, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35330827
18.
Treatment patterns and outcomes of immunotherapy in extensive-stage small-cell lung cancer based on real-world practice.
Thorac Cancer
; 13(23): 3295-3303, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36218023
19.
Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon EGFR Mutations: A Comparative Cohort Study in China (AFANDA Study).
Cancers (Basel)
; 14(21)2022 Oct 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36358728
20.
Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment.
Front Oncol
; 11: 649843, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33937055